论文部分内容阅读
胰腺癌是恶性程度最高的消化道肿瘤之一，其5年生存率仍然不足10%。手术是胰腺癌长期生存的基础。随着化疗方案的进步，新辅助治疗逐步在胰腺癌中得到开展。关于新辅助治疗对胰腺癌围手术期并发症影响的研究日益增多，但不同研究的结果并不一致。本研究回顾性分析了近年来胰腺癌新辅助治疗的相关研究，探讨了一些关键因素对围手术期并发症的影响。“,”Pancreatic cancer is one of the most malignant digestive tract tumors with a 5-year survival rate of less than 10%. Surgery remains the basis of long-term survival of pancreatic cancer patients. With the progress of chemotherapy, neoadjuvant therapy has been gradually carried out in pancreatic cancer. There are more and more studies on the effects of neoadjuvant therapy on perioperative complications of pancreatic cancer, but the results are not consistent. This article reviews the recent studies on neoadjuvant therapy for pancreatic cancer and analyzes the impact of some key factors on perioperative complications.